Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Drug Des Devel Ther ; 14: 4963-4974, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33235437

RESUMEN

Palmatine is a naturally occurring isoquinoline alkaloid with various pharmacological properties. Given its antioxidant and anti-inflammatory properties, palmatine may be able to impede the effects of metabolic syndrome (MetS) and its related diseases triggered by inflammation and oxidative stress. This review summarises the existing literature about the effects of palmatine supplementation on MetS and its complications. The evidence shows that palmatine could protect against MetS, and cardiovascular diseases, osteoporosis and osteoarthritis, which might be associated with MetS. These protective effects are mediated by the antioxidant and anti-inflammatory properties of palmatine. Although preclinical experiments have demonstrated the efficacy of palmatine against MetS and its related diseases, no human clinical trials have been performed to validate these effects. This research gap should be bridged to validate the efficacy and safety of palmatine supplementation in protecting humans against MetS and its related diseases.


Asunto(s)
Antiinflamatorios/farmacología , Antioxidantes/farmacología , Alcaloides de Berberina/farmacología , Inflamación/tratamiento farmacológico , Síndrome Metabólico/tratamiento farmacológico , Antiinflamatorios/efectos adversos , Antioxidantes/efectos adversos , Alcaloides de Berberina/efectos adversos , Humanos , Inflamación/metabolismo , Síndrome Metabólico/metabolismo , Estrés Oxidativo/efectos de los fármacos
2.
J Clin Pharmacol ; 57(2): 151-160, 2017 02.
Artículo en Inglés | MEDLINE | ID: mdl-27363313

RESUMEN

Cocaine use disorder (CUD) remains a significant public health challenge. l-Tetrahydropalmatine (l-THP), a well-tolerated and nonaddictive compound, shows promise for the management of CUD. Its pharmacologic profile includes blockade at dopamine and other monoamine receptors and attenuation of cocaine self-administration, reinstatement, and rewarding properties in rats. This study evaluated the safety of l-THP in human cocaine users and its influence on the safety and pharmacokinetics (PK) of cocaine. Twenty-four cocaine-using adult men were randomized to receive l-THP (30 mg twice a day orally) or placebo double-blind for 4 days, with an intranasal cocaine (40 mg) challenge on the fourth day. Safety and tolerability were evaluated using vital signs, ECG, clinical laboratory tests, and standardized self-report instruments. Peripheral venous blood was collected periodically and later assayed for l-THP and cocaine using highly sensitive and specific ultraperformance liquid chromatography-fluorescence detection (UPLC-FLD) methods. Twenty subjects completed the study, of whom 19 provided complete PK data. The short 3.5-day course of l-THP was safe and well tolerated and did not affect cocaine's PK or its acute cardiovascular effects. The cocaine AUC0→∞ was 211.5 and 261.4 h·ng/mL, and the Cmax was 83.3 and 104.5 ng/mL for the l-THP and placebo groups, respectively. In addition there were no significant differences in the number of side effects reported in each group (l-THP group 22 [48%], placebo group 24 [52%]) or vital signs including, heart rate, blood pressure, complete blood count, or ECG. These findings suggest that oral THP has promise for further development as a treatment for CUD.


Asunto(s)
Alcaloides de Berberina/farmacocinética , Trastornos Relacionados con Cocaína/metabolismo , Antagonistas de Dopamina/farmacocinética , Administración Intranasal , Adulto , Alcaloides de Berberina/efectos adversos , Cromatografía Líquida de Alta Presión , Cocaína/administración & dosificación , Cocaína/farmacología , Antagonistas de Dopamina/efectos adversos , Método Doble Ciego , Electrocardiografía/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Espectrometría de Fluorescencia
3.
J Invest Surg ; 30(2): 116-124, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-27690697

RESUMEN

Purpose/Aim: Oxidative stress plays an important role in the pathogenesis of acute pancreatitis (AP). We compared the therapeutic effects of Ukrain (NSC 631570) and N-acetylcysteine (NAC) in rats with AP. MATERIALS AND METHODS: Forty male Sprague Dawley rats were divided into four groups: controls; AP; AP with NAC; and AP with Ukrain. AP was induced via the ligation of the bile-pancreatic duct; drugs were administered intraperitoneally (i.p.) 30 min and 12 h after AP induction. Twenty-four hours after AP induction, animals were sacrificed and the pancreas was excised. Levels of malondialdehyde (MDA) and nitric oxide (NO), and activity levels of tumor necrosis factor (TNF)-α, and myeloperoxidase (MPO) were measured in tissue samples. Total oxidant status (TOS), total antioxidant status (TAS), and total bilirubin, as well as activity levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), amylase and lipase were measured in serum samples. Pancreatic tissue histopathology was also evaluated. RESULTS: Test drugs reduced levels of MDA, NO, TNF-α, total bilirubin, AST, ALT, TOS and MPO, amylase and lipase activities (P < 0.001), and increased TAS (P < 0.001). Rats treated with test drugs attenuated AP-induced morphologic changes and decreased pancreatic damage scores compared with the AP group (P < 0.05). Both test drugs attenuated pancreatic damage, but the therapeutic effect was more pronounced in rats that received Ukrain than in those receiving NAC. CONCLUSIONS: These results suggest that treatment with Ukrain or NAC can reduce pancreatic damage via anti-inflammatory and antioxidant effects.


Asunto(s)
Acetilcisteína/uso terapéutico , Antioxidantes/uso terapéutico , Alcaloides de Berberina/uso terapéutico , Sistema Biliar/efectos de los fármacos , Pancreatitis/tratamiento farmacológico , Fenantridinas/uso terapéutico , Acetilcisteína/administración & dosificación , Acetilcisteína/efectos adversos , Alanina Transaminasa/sangre , Amilasas/sangre , Animales , Antioxidantes/administración & dosificación , Antioxidantes/efectos adversos , Aspartato Aminotransferasas/sangre , Alcaloides de Berberina/administración & dosificación , Alcaloides de Berberina/efectos adversos , Bilirrubina/sangre , Modelos Animales de Enfermedad , Humanos , Lipasa/sangre , Masculino , Malondialdehído/sangre , Óxido Nítrico/metabolismo , Oxidantes/sangre , Estrés Oxidativo/efectos de los fármacos , Páncreas/metabolismo , Páncreas/patología , Pancreatitis/sangre , Pancreatitis/metabolismo , Pancreatitis/patología , Peroxidasa/metabolismo , Fenantridinas/administración & dosificación , Fenantridinas/efectos adversos , Ratas , Ratas Sprague-Dawley , Factor de Necrosis Tumoral alfa/metabolismo
4.
Arch Intern Med ; 156(8): 899-903, 1996 Apr 22.
Artículo en Inglés | MEDLINE | ID: mdl-8774209

RESUMEN

Herbal medications and other nontraditional medical therapies are becoming increasingly popular in the United States. We describe three children and three adults in whom severe toxic effects developed after ingestion of a Chinese herbal medication, jin bu huan, which is sold as Jin Bu Huan Anodyne Tablets. Jin bu huan produced distinct clinical syndromes after acute ingestion in children and long-term use in adults. A single, acute ingestion in children rapidly produced life-threatening neurologic and cardiovascular manifestations, while long-term jin bu huan use in adults was associated with hepatitis. Jin bu huan contains levo-tetrahydropalmatine, a potent neuroactive substance. The constituents of jin bu huan are misidentified on the package, resulting in significant delay in identifying the plant alkaloid responsible for its toxicity. Although perceived as innocuous, jin bu huan may produce major health effects. The highly concentrated formulation, the lack of childproof packaging, and the product insert listing indications for the treatment of serious medical conditions may all contribute to the development of toxic reactions.


Asunto(s)
Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Coma/inducido químicamente , Medicamentos Herbarios Chinos/efectos adversos , Anciano , Alcaloides de Berberina/efectos adversos , Preescolar , Etiquetado de Medicamentos , Medicamentos Herbarios Chinos/química , Femenino , Humanos , Lactante , Masculino , Persona de Mediana Edad , Estados Unidos , United States Food and Drug Administration
5.
Pharmacology ; 51(4): 237-44, 1995 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-8577817

RESUMEN

The effects of DL-tetrahydropalmatine (THP; a main active substance of the Chinese herb corydalis), haloperidol (a dopamine D2 receptor antagonist), apomorphine and amphetamine on cardiovascular function and striatal dopamine (DA) release were compared in rats under general anesthesia. Intravenous administration of THP (1-10 mg/kg) or haloperidol (0.5-1.25 mg/kg) produced hypotension, bradycardia and increased DA release in the striatum. On the other hand, amphetamine (0.5-1.25 mg/kg) produced hypertension, tachycardia and increased striatal DA release. However, intravenous injection of apomorphine (0.5-1.25 mg/kg) produced hypotension, bradycardia and decreased striatal DA release. In addition, the THP-induced hypotension was attenuated by pretreatment with spinal transection or amphetamine, while the THP-induced bradycardia was attenuated by pretreatment with bilateral vagotomy or amphetamine. Thus, it appears that THP acts through DA D2 receptor antagonism to induce hypotension and bradycardia in rats.


Asunto(s)
Antihipertensivos/efectos adversos , Alcaloides de Berberina/efectos adversos , Bradicardia/inducido químicamente , Antagonistas de Dopamina/efectos adversos , Dopamina/metabolismo , Hipotensión/inducido químicamente , Anfetamina/administración & dosificación , Anfetamina/efectos adversos , Análisis de Varianza , Animales , Antihipertensivos/administración & dosificación , Apomorfina/administración & dosificación , Apomorfina/efectos adversos , Alcaloides de Berberina/administración & dosificación , Cuerpo Estriado/efectos de los fármacos , Cuerpo Estriado/metabolismo , Dopaminérgicos/administración & dosificación , Dopaminérgicos/efectos adversos , Agonistas de Dopamina/administración & dosificación , Agonistas de Dopamina/efectos adversos , Antagonistas de Dopamina/administración & dosificación , Haloperidol/administración & dosificación , Haloperidol/efectos adversos , Frecuencia Cardíaca/efectos de los fármacos , Inyecciones Intravenosas , Masculino , Ratas , Ratas Sprague-Dawley , Receptores de Dopamina D2/efectos de los fármacos , Estereoisomerismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...